VCNX: רווח נקי למניה (EPS TTM) Vaccinex, Inc
Vaccinex, Inc. (VCNX) possesses robust R&D potential driven by its pepinemab platform for cancer treatment. The TTM net income per share reflects profit dynamics, where a metric value of 7.44 serves as an indicator of resilience. US-based operations are shielded from trade conflicts, while production outsourcing allows the team to maintain flexibility without incurring unnecessary costs.
פילוחי נתונים אנליטיים מרוכזים עבור Vaccinex Inc. (VCNX)
Net income per share for Vaccinex, Inc. (VCNX) is calculated as the ratio of total annual income to the total number of securities. This indicator filters out market noise, demonstrating real profitability trends without the influence of one-off transactions. The current value of 7.44 reflects financial pressure caused by costs associated with cancer therapy clinical trials. Risks regarding the prolongation of contracts with pharma behemoths make the 12-month rolling EPS a critical marker of stability. Analyzing this trend helps avoid investing in an asset with depleting capital.
